25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Pfizer Inc CDR
Buy, Hold or Sell?

Let's analyze Pfizer together

I guess you are interested in Pfizer Inc CDR. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pfizer Inc CDR. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Pfizer Inc CDR

I send you an email if I find something interesting about Pfizer Inc CDR.

1. Quick Overview

1.1. Quick analysis of Pfizer (30 sec.)










1.2. What can you expect buying and holding a share of Pfizer? (30 sec.)

How much money do you get?

How much money do you get?
C$0.40
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
C$5.27
Expected worth in 1 year
C$4.59
How sure are you?
85.7%

+ What do you gain per year?

Total Gains per Share
C$-0.12
Return On Investment
-0.9%

For what price can you sell your share?

Current Price per Share
C$13.08
Expected price per share
C$12.59 - C$14.16
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Pfizer (5 min.)




Live pricePrice per Share (EOD)
C$13.08
Intrinsic Value Per Share
C$-30.17 - C$-36.74
Total Value Per Share
C$-24.90 - C$-31.47

2.2. Growth of Pfizer (5 min.)




Is Pfizer growing?

Current yearPrevious yearGrowGrow %
How rich?$63b$69.7b-$3.9b-6.1%

How much money is Pfizer making?

Current yearPrevious yearGrowGrow %
Making money-$648.7m$5.3b-$6b-927.5%
Net Profit Margin-5.1%26.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Pfizer (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Pfizer?

Welcome investor! Pfizer's management wants to use your money to grow the business. In return you get a share of Pfizer.

First you should know what it really means to hold a share of Pfizer. And how you can make/lose money.

Speculation

The Price per Share of Pfizer is C$13.08. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pfizer.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pfizer, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is C$5.27. Based on the TTM, the Book Value Change Per Share is C$-0.17 per quarter. Based on the YOY, the Book Value Change Per Share is C$0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is C$0.14 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pfizer.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 C$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per Share
Usd Eps0.000.0%-0.04-0.3%0.322.5%0.251.9%0.251.9%
Usd Book Value Change Per Share-0.20-1.5%-0.12-0.9%0.131.0%0.272.1%0.272.1%
Usd Dividend Per Share0.100.8%0.100.8%0.100.7%0.100.7%0.100.7%
Usd Total Gains Per Share-0.09-0.7%-0.02-0.2%0.221.7%0.372.8%0.372.8%
Usd Price Per Share9.38-9.91-14.75-11.07-11.07-
Price to Earnings Ratio954.05-233.73-13.69-73.70-73.70-
Price-to-Total Gains Ratio-99.08-265.16-236.31-204.56-204.56-
Price to Book Ratio2.48-2.51-3.54-2.87-2.87-
Price-to-Total Gains Ratio-99.08-265.16-236.31-204.56-204.56-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.375744
Number of shares106
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.100.10
Usd Book Value Change Per Share-0.120.27
Usd Total Gains Per Share-0.020.37
Gains per Quarter (106 shares)-2.2038.93
Gains per Year (106 shares)-8.82155.72
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
143-52-1941114146
285-103-2883229302
3128-155-37124343458
4171-206-46165458614
5214-258-55206572770
6256-309-64248687926
7299-361-732898011082
8342-412-823309161238
9384-464-9137110301394
10427-515-10041311441550

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%10.02.00.083.3%12.02.00.085.7%12.02.00.085.7%12.02.00.085.7%
Book Value Change Per Share1.03.00.025.0%8.04.00.066.7%10.04.00.071.4%10.04.00.071.4%10.04.00.071.4%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%14.00.00.0100.0%14.00.00.0100.0%14.00.00.0100.0%
Total Gains per Share2.02.00.050.0%10.02.00.083.3%12.02.00.085.7%12.02.00.085.7%12.02.00.085.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Pfizer Inc CDR compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.275-0.170-38%0.177-255%0.377-173%0.377-173%
Book Value Per Share--5.2725.499-4%5.833-10%5.218+1%5.218+1%
Current Ratio--0.8631.299-34%1.573-45%1.424-39%1.424-39%
Debt To Asset Ratio--0.5930.582+2%0.517+15%0.557+6%0.557+6%
Debt To Equity Ratio--1.4621.403+4%1.080+35%1.274+15%1.274+15%
Dividend Per Share--0.1430.141+1%0.137+4%0.136+5%0.136+5%
Eps--0.003-0.054+1682%0.449-99%0.350-99%0.350-99%
Free Cash Flow Per Share---0.1450.072-301%0.160-191%0.251-158%0.251-158%
Free Cash Flow To Equity Per Share---0.292-0.014-95%0.813-136%0.318-192%0.318-192%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---36.744--------
Intrinsic Value_10Y_min---30.175--------
Intrinsic Value_1Y_max--0.218--------
Intrinsic Value_1Y_min--0.216--------
Intrinsic Value_3Y_max---2.318--------
Intrinsic Value_3Y_min---2.153--------
Intrinsic Value_5Y_max---8.437--------
Intrinsic Value_5Y_min---7.575--------
Market Cap218267266744.3200%218267266744.320230782591672.320-5%343295362775.040-36%257601145089.463-15%257601145089.463-15%
Net Profit Margin--0.003-0.051+1752%0.268-99%0.189-98%0.189-98%
Operating Margin----0%0.314-100%0.222-100%0.222-100%
Operating Ratio--1.0781.409-23%1.006+7%1.141-6%1.141-6%
Pb Ratio2.4810%2.4812.513-1%3.539-30%2.869-14%2.869-14%
Pe Ratio954.0490%954.049233.727+308%13.686+6871%73.702+1194%73.702+1194%
Price Per Share13.0800%13.08013.830-5%20.573-36%15.437-15%15.437-15%
Price To Free Cash Flow Ratio-22.5670%-22.56739.154-158%276.270-108%94.114-124%94.114-124%
Price To Total Gains Ratio-99.0770%-99.077265.158-137%236.306-142%204.561-148%204.561-148%
Quick Ratio--0.3980.765-48%1.149-65%0.965-59%0.965-59%
Return On Assets--0.000-0.004+1639%0.038-99%0.032-99%0.032-99%
Return On Equity--0.001-0.010+1608%0.078-99%0.070-99%0.070-99%
Total Gains Per Share---0.132-0.029-78%0.314-142%0.512-126%0.512-126%
Usd Book Value--63060480000.00065770880000.000-4%69769011200.000-10%62419148800.000+1%62419148800.000+1%
Usd Book Value Change Per Share---0.197-0.122-38%0.127-255%0.270-173%0.270-173%
Usd Book Value Per Share--3.7793.941-4%4.181-10%3.741+1%3.741+1%
Usd Dividend Per Share--0.1020.101+1%0.098+4%0.097+5%0.097+5%
Usd Eps--0.002-0.039+1682%0.322-99%0.251-99%0.251-99%
Usd Free Cash Flow---1733222400.000861952000.000-301%1911168000.000-191%3003443200.000-158%3003443200.000-158%
Usd Free Cash Flow Per Share---0.1040.052-301%0.115-191%0.180-158%0.180-158%
Usd Free Cash Flow To Equity Per Share---0.209-0.010-95%0.582-136%0.228-192%0.228-192%
Usd Market Cap156453976802.3290%156453976802.329165424961710.719-5%246074116037.149-36%184648500800.127-15%184648500800.127-15%
Usd Price Per Share9.3760%9.3769.913-5%14.746-36%11.065-15%11.065-15%
Usd Profit--40997376.000-648708480.000+1682%5367906432.000-99%4187374848.000-99%4187374848.000-99%
Usd Revenue--13282149888.00013909609728.000-5%19484752896.000-32%19161416448.000-31%19161416448.000-31%
Usd Total Gains Per Share---0.095-0.021-78%0.225-142%0.367-126%0.367-126%
 EOD+0 -1MRQTTM+12 -22YOY+5 -305Y+9 -2610Y+9 -26

3.3 Fundamental Score

Let's check the fundamental score of Pfizer Inc CDR based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15954.049
Price to Book Ratio (EOD)Between0-12.481
Net Profit Margin (MRQ)Greater than00.003
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.398
Current Ratio (MRQ)Greater than10.863
Debt to Asset Ratio (MRQ)Less than10.593
Debt to Equity Ratio (MRQ)Less than11.462
Return on Equity (MRQ)Greater than0.150.001
Return on Assets (MRQ)Greater than0.050.000
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Pfizer Inc CDR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.692
Ma 20Greater thanMa 5013.500
Ma 50Greater thanMa 10013.537
Ma 100Greater thanMa 20013.431
OpenGreater thanClose13.270
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Pfizer Inc CDR

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2024-10-12 13:54:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Pfizer earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 0.3% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pfizer Inc CDR:

  • The MRQ is 0.3%. The company is not making a profit/loss.
  • The TTM is -5.1%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ0.3%TTM-5.1%+5.4%
TTM-5.1%YOY26.8%-31.9%
TTM-5.1%5Y18.9%-24.0%
5Y18.9%10Y18.9%0.0%
4.3.1.2. Return on Assets

Shows how efficient Pfizer is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • 0.0% Return on Assets means that Pfizer generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pfizer Inc CDR:

  • The MRQ is 0.0%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -0.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.0%TTM-0.4%+0.4%
TTM-0.4%YOY3.8%-4.2%
TTM-0.4%5Y3.2%-3.6%
5Y3.2%10Y3.2%0.0%
4.3.1.3. Return on Equity

Shows how efficient Pfizer is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • 0.1% Return on Equity means Pfizer generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pfizer Inc CDR:

  • The MRQ is 0.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -1.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.1%TTM-1.0%+1.0%
TTM-1.0%YOY7.8%-8.8%
TTM-1.0%5Y7.0%-8.0%
5Y7.0%10Y7.0%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Pfizer Inc CDR.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Pfizer is operating .

  • Measures how much profit Pfizer makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pfizer Inc CDR:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY31.4%-31.4%
TTM-5Y22.2%-22.2%
5Y22.2%10Y22.2%0.0%
4.3.2.2. Operating Ratio

Measures how efficient Pfizer is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 1.08 means that the operating costs are $1.08 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Pfizer Inc CDR:

  • The MRQ is 1.078. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.409. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.078TTM1.409-0.331
TTM1.409YOY1.006+0.403
TTM1.4095Y1.141+0.268
5Y1.14110Y1.1410.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Pfizer Inc CDR.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Pfizer is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 0.86 means the company has $0.86 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Pfizer Inc CDR:

  • The MRQ is 0.863. The company is just not able to pay all its short-term debts. -1
  • The TTM is 1.299. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ0.863TTM1.299-0.435
TTM1.299YOY1.573-0.274
TTM1.2995Y1.424-0.125
5Y1.42410Y1.4240.000
4.4.3.2. Quick Ratio

Measures if Pfizer is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.40 means the company can pay off $0.40 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pfizer Inc CDR:

  • The MRQ is 0.398. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.765. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.398TTM0.765-0.367
TTM0.765YOY1.149-0.384
TTM0.7655Y0.965-0.200
5Y0.96510Y0.9650.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Pfizer Inc CDR.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Pfizer assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pfizer to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.59 means that Pfizer assets are financed with 59.3% credit (debt) and the remaining percentage (100% - 59.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pfizer Inc CDR:

  • The MRQ is 0.593. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.582. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.593TTM0.582+0.011
TTM0.582YOY0.517+0.065
TTM0.5825Y0.557+0.025
5Y0.55710Y0.5570.000
4.5.4.2. Debt to Equity Ratio

Measures if Pfizer is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 146.2% means that company has $1.46 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pfizer Inc CDR:

  • The MRQ is 1.462. The company is able to pay all its debts with equity. +1
  • The TTM is 1.403. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.462TTM1.403+0.059
TTM1.403YOY1.080+0.323
TTM1.4035Y1.274+0.129
5Y1.27410Y1.2740.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Pfizer generates.

  • Above 15 is considered overpriced but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • A PE ratio of 954.05 means the investor is paying $954.05 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pfizer Inc CDR:

  • The EOD is 954.049. Based on the earnings, the company is expensive. -2
  • The MRQ is 954.049. Based on the earnings, the company is expensive. -2
  • The TTM is 233.727. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD954.049MRQ954.0490.000
MRQ954.049TTM233.727+720.322
TTM233.727YOY13.686+220.040
TTM233.7275Y73.702+160.025
5Y73.70210Y73.7020.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pfizer Inc CDR:

  • The EOD is -22.567. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -22.567. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 39.154. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-22.567MRQ-22.5670.000
MRQ-22.567TTM39.154-61.721
TTM39.154YOY276.270-237.117
TTM39.1545Y94.114-54.960
5Y94.11410Y94.1140.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Pfizer is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 2.48 means the investor is paying $2.48 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Pfizer Inc CDR:

  • The EOD is 2.481. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.481. Based on the equity, the company is underpriced. +1
  • The TTM is 2.513. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.481MRQ2.4810.000
MRQ2.481TTM2.513-0.032
TTM2.513YOY3.539-1.026
TTM2.5135Y2.869-0.356
5Y2.86910Y2.8690.000
4.6.2. Total Gains per Share

2.4. Latest News of Pfizer Inc CDR

Does Pfizer Inc CDR still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Pfizer Inc CDR to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2024-10-31
21:09
Is Novavax Stock A Sell After An Unexpected Side Effect Torpedoed Its Testing Plans?Read
2024-10-29
19:47
Pfizer is racing to get in on the weight loss drug boomRead
2024-10-29
17:08
Pfizer is getting another COVID-19 sales boostRead
2024-10-26
13:00
Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’tRead
2024-10-22
23:22
Pfizer Receives FDA Approval for RSV VaccineRead
2024-10-22
15:09
Starboard Chief Criticizes Pfizer’s R&D InvestmentsRead
2024-10-21
17:32
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake SaleRead
2024-10-21
16:18
Pfizer Inc. (PFE): Among the Worst Performing Blue Chip Stocks in 2024Read
2024-10-19
22:53
Goldman Sachs: Pfizer Inc. (NYSE:PFE) Is A Stock With High Consensus ROERead
2024-10-19
02:59
He Made Pfizer a Household Name. Wall Street Wants More.Read
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in CAD. All numbers in thousands.

Summary
Total Assets216,193,000
Total Liabilities128,218,000
Total Stockholder Equity87,700,000
 As reported
Total Liabilities 128,218,000
Total Stockholder Equity+ 87,700,000
Total Assets = 216,193,000

Assets

Total Assets216,193,000
Total Current Assets37,825,000
Long-term Assets178,367,000
Total Current Assets
Cash And Cash Equivalents 1,052,000
Short-term Investments 6,049,000
Net Receivables 11,393,000
Inventory 11,447,000
Other Current Assets 4,190,000
Total Current Assets  (as reported)37,825,000
Total Current Assets  (calculated)34,131,000
+/- 3,694,000
Long-term Assets
Property Plant Equipment 18,957,000
Goodwill 68,445,000
Long Term Investments 11,148,000
Intangible Assets 61,240,000
Long-term Assets Other 10,710,000
Long-term Assets  (as reported)178,367,000
Long-term Assets  (calculated)170,500,000
+/- 7,867,000

Liabilities & Shareholders' Equity

Total Current Liabilities43,819,000
Long-term Liabilities84,399,000
Total Stockholder Equity87,700,000
Total Current Liabilities
Short Long Term Debt 11,944,000
Accounts payable 5,106,000
Other Current Liabilities 16,411,000
Total Current Liabilities  (as reported)43,819,000
Total Current Liabilities  (calculated)33,461,000
+/- 10,358,000
Long-term Liabilities
Long term Debt 56,733,000
Long-term Liabilities Other 16,094,000
Long-term Liabilities  (as reported)84,399,000
Long-term Liabilities  (calculated)72,827,000
+/- 11,572,000
Total Stockholder Equity
Retained Earnings 116,596,000
Total Stockholder Equity (as reported)87,700,000
Total Stockholder Equity (calculated)116,596,000
+/- 28,896,000
Other
Capital Stock480,000
Common Stock Shares Outstanding 5,666,593
Net Debt 67,625,000
Net Invested Capital 156,377,000
Net Working Capital -5,994,000
Property Plant and Equipment Gross 35,529,000



6.2. Balance Sheets Structured

Currency in CAD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-31
> Total Assets 
158,818,000
169,920,000
179,188,000
181,476,000
183,841,000
195,290,000
195,350,000
197,205,000
195,617,000
220,168,000
215,021,000
226,501,000
221,095,000
216,193,000
216,193,000221,095,000226,501,000215,021,000220,168,000195,617,000197,205,000195,350,000195,290,000183,841,000181,476,000179,188,000169,920,000158,818,000
   > Total Current Assets 
39,533,000
48,814,000
57,900,000
59,693,000
54,420,000
67,466,000
70,403,000
51,259,000
50,078,000
73,347,000
74,012,000
43,333,000
42,415,000
37,825,000
37,825,00042,415,00043,333,00074,012,00073,347,00050,078,00051,259,00070,403,00067,466,00054,420,00059,693,00057,900,00048,814,00039,533,000
       Cash And Cash Equivalents 
1,768,000
2,372,000
1,966,000
1,944,000
2,470,000
1,780,000
1,298,000
416,000
2,166,000
2,632,000
3,148,000
2,853,000
719,000
1,052,000
1,052,000719,0002,853,0003,148,0002,632,0002,166,000416,0001,298,0001,780,0002,470,0001,944,0001,966,0002,372,0001,768,000
       Short-term Investments 
11,899,000
19,328,000
27,730,000
29,125,000
21,427,000
31,524,000
34,825,000
22,316,000
17,806,000
42,153,000
41,033,000
9,837,000
11,210,000
6,049,000
6,049,00011,210,0009,837,00041,033,00042,153,00017,806,00022,316,00034,825,00031,524,00021,427,00029,125,00027,730,00019,328,00011,899,000
       Net Receivables 
9,864,000
14,348,000
15,774,000
15,745,000
16,342,000
17,738,000
18,620,000
14,529,000
15,445,000
13,425,000
11,086,000
11,177,000
10,989,000
11,393,000
11,393,00010,989,00011,177,00011,086,00013,425,00015,445,00014,529,00018,620,00017,738,00016,342,00015,745,00015,774,00014,348,0009,864,000
       Inventory 
8,493,000
8,948,000
8,640,000
9,059,000
9,979,000
10,454,000
9,513,000
8,981,000
9,541,000
10,310,000
10,204,000
10,189,000
10,892,000
11,447,000
11,447,00010,892,00010,189,00010,204,00010,310,0009,541,0008,981,0009,513,00010,454,0009,979,0009,059,0008,640,0008,948,0008,493,000
       Other Current Assets 
4,090,000
3,816,000
3,784,000
3,816,000
4,197,000
5,962,000
6,138,000
5,017,000
5,120,000
4,827,000
4,624,000
5,299,000
4,372,000
4,190,000
4,190,0004,372,0005,299,0004,624,0004,827,0005,120,0005,017,0006,138,0005,962,0004,197,0003,816,0003,784,0003,816,0004,090,000
   > Long-term Assets 
119,284,000
121,106,000
121,288,000
121,782,000
129,420,000
127,824,000
124,946,000
145,944,000
145,539,000
146,822,000
141,009,000
183,168,000
178,680,000
178,367,000
178,367,000178,680,000183,168,000141,009,000146,822,000145,539,000145,944,000124,946,000127,824,000129,420,000121,782,000121,288,000121,106,000119,284,000
       Property Plant Equipment 
0
14,224,000
14,436,000
17,721,000
15,109,000
15,244,000
15,441,000
16,274,000
17,052,000
17,488,000
17,862,000
18,940,000
18,803,000
18,957,000
18,957,00018,803,00018,940,00017,862,00017,488,00017,052,00016,274,00015,441,00015,244,00015,109,00017,721,00014,436,00014,224,0000
       Goodwill 
49,791,000
49,867,000
49,489,000
49,208,000
50,211,000
49,891,000
49,441,000
51,375,000
51,476,000
51,572,000
51,527,000
67,783,000
69,297,000
68,445,000
68,445,00069,297,00067,783,00051,527,00051,572,00051,476,00051,375,00049,441,00049,891,00050,211,00049,208,00049,489,00049,867,00049,791,000
       Long Term Investments 
20,228,000
20,942,000
21,597,000
21,526,000
20,737,000
18,963,000
13,888,000
15,069,000
14,743,000
15,066,000
14,238,000
15,368,000
11,613,000
11,148,000
11,148,00011,613,00015,368,00014,238,00015,066,00014,743,00015,069,00013,888,00018,963,00020,737,00021,526,00021,597,00020,942,00020,228,000
       Intangible Assets 
27,973,000
27,323,000
26,306,000
25,146,000
29,816,000
29,065,000
28,150,000
43,370,000
42,001,000
41,407,000
40,224,000
64,900,000
62,828,000
61,240,000
61,240,00062,828,00064,900,00040,224,00041,407,00042,001,00043,370,00028,150,00029,065,00029,816,00025,146,00026,306,00027,323,00027,973,000
       Long-term Assets Other 
4,744,000
6,056,000
6,705,000
7,679,000
7,879,000
7,659,000
10,890,000
13,163,000
12,965,000
13,028,000
8,808,000
12,471,000
11,197,000
10,710,000
10,710,00011,197,00012,471,0008,808,00013,028,00012,965,00013,163,00010,890,0007,659,0007,879,0007,679,0006,705,0006,056,0004,744,000
> Total Liabilities 
89,953,000
99,605,000
103,221,000
104,014,000
101,156,000
107,821,000
102,459,000
101,289,000
94,381,000
120,875,000
117,817,000
137,213,000
128,537,000
128,218,000
128,218,000128,537,000137,213,000117,817,000120,875,00094,381,000101,289,000102,459,000107,821,000101,156,000104,014,000103,221,00099,605,00089,953,000
   > Total Current Liabilities 
26,652,000
35,664,000
41,803,000
42,671,000
39,268,000
47,410,000
44,314,000
42,138,000
36,562,000
34,647,000
31,136,000
47,794,000
40,497,000
43,819,000
43,819,00040,497,00047,794,00031,136,00034,647,00036,562,00042,138,00044,314,00047,410,00039,268,00042,671,00041,803,00035,664,00026,652,000
       Short Long Term Debt 
4,352,000
3,888,000
3,629,000
2,241,000
636,000
5,990,000
4,024,000
2,945,000
4,189,000
3,985,000
2,548,000
10,346,000
8,231,000
11,944,000
11,944,0008,231,00010,346,0002,548,0003,985,0004,189,0002,945,0004,024,0005,990,000636,0002,241,0003,629,0003,888,0004,352,000
       Accounts payable 
4,064,000
4,327,000
4,698,000
5,578,000
5,506,000
6,208,000
6,267,000
6,809,000
6,123,000
6,081,000
5,338,000
6,710,000
5,591,000
5,106,000
5,106,0005,591,0006,710,0005,338,0006,081,0006,123,0006,809,0006,267,0006,208,0005,506,0005,578,0004,698,0004,327,0004,064,000
       Other Current Liabilities 
12,798,000
21,690,000
26,965,000
26,732,000
26,570,000
28,882,000
26,746,000
23,438,000
20,254,000
17,314,000
16,776,000
20,541,000
18,789,000
16,411,000
16,411,00018,789,00020,541,00016,776,00017,314,00020,254,00023,438,00026,746,00028,882,00026,570,00026,732,00026,965,00021,690,00012,798,000
   > Long-term Liabilities 
63,301,000
63,941,000
61,418,000
61,343,000
61,888,000
60,411,000
58,145,000
59,151,000
57,819,000
86,228,000
86,681,000
89,419,000
88,040,000
84,399,000
84,399,00088,040,00089,419,00086,681,00086,228,00057,819,00059,151,00058,145,00060,411,00061,888,00061,343,00061,418,00063,941,00063,301,000
       Long term Debt 
33,836,000
33,847,000
34,779,000
34,757,000
34,416,000
34,294,000
31,653,000
31,925,000
30,738,000
61,356,000
61,048,000
60,499,000
60,477,000
56,733,000
56,733,00060,477,00060,499,00061,048,00061,356,00030,738,00031,925,00031,653,00034,294,00034,416,00034,757,00034,779,00033,847,00033,836,000
       Other Liabilities 
0
28,587,000
25,169,000
22,637,000
26,092,000
25,911,000
25,187,000
23,348,000
0
24,554,000
0
0
0
0
000024,554,000023,348,00025,187,00025,911,00026,092,00022,637,00025,169,00028,587,0000
       Long-term Liabilities Other 
6,678,000
8,228,000
9,202,000
9,744,000
10,509,000
11,312,000
12,239,000
13,182,000
13,009,000
13,404,000
14,243,000
16,540,000
15,123,000
16,094,000
16,094,00015,123,00016,540,00014,243,00013,404,00013,009,00013,182,00012,239,00011,312,00010,509,0009,744,0009,202,0008,228,0006,678,000
> Total Stockholder Equity
68,620,000
70,042,000
75,691,000
77,201,000
82,424,000
87,208,000
92,631,000
95,661,000
100,970,000
99,019,000
96,934,000
89,014,000
92,282,000
87,700,000
87,700,00092,282,00089,014,00096,934,00099,019,000100,970,00095,661,00092,631,00087,208,00082,424,00077,201,00075,691,00070,042,00068,620,000
   Common Stock
0
472,000
473,000
473,000
476,000
476,000
476,000
476,000
0
478,000
0
0
0
0
0000478,0000476,000476,000476,000476,000473,000473,000472,0000
   Retained Earnings 
95,158,000
96,346,000
102,252,000
103,394,000
111,193,000
116,608,000
122,967,000
125,656,000
131,102,000
128,796,000
126,411,000
118,353,000
121,318,000
116,596,000
116,596,000121,318,000118,353,000126,411,000128,796,000131,102,000125,656,000122,967,000116,608,000111,193,000103,394,000102,252,00096,346,00095,158,000
   Capital Surplus 00000000000000
   Treasury Stock00000000000000
   Other Stockholders Equity 0000-8,102,000-8,290,000-8,304,000-8,226,000-7,120,000-6,158,000-5,896,000-5,648,000-4,756,0000



6.3. Balance Sheets

Currency in CAD. All numbers in thousands.




6.4. Cash Flows

Currency in CAD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in CAD. All numbers in thousands.

Gross Profit (+$)
totalRevenue58,496,000
Cost of Revenue-24,954,000
Gross Profit33,542,00033,542,000
 
Operating Income (+$)
Gross Profit33,542,000
Operating Expense-55,137,000
Operating Income3,359,000-21,595,000
 
Operating Expense (+$)
Research Development10,679,000
Selling General Administrative14,771,000
Selling And Marketing Expenses-
Operating Expense55,137,00025,450,000
 
Net Interest Income (+$)
Interest Income1,624,000
Interest Expense-2,209,000
Other Finance Cost-0
Net Interest Income-585,000
 
Pretax Income (+$)
Operating Income3,359,000
Net Interest Income-585,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)1,058,0005,075,000
EBIT - interestExpense = -2,209,000
2,119,000
4,328,000
Interest Expense2,209,000
Earnings Before Interest and Taxes (EBIT)-3,267,000
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax1,058,000
Tax Provision--1,115,000
Net Income From Continuing Ops2,172,0002,173,000
Net Income2,119,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-1,716,000585,000
 

Technical Analysis of Pfizer
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pfizer. The general trend of Pfizer is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pfizer's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pfizer Inc CDR.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 13.14 < 13.15 < 14.16.

The bearish price targets are: 13.10 > 13.00 > 12.59.

Tweet this
Pfizer Inc CDR Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pfizer Inc CDR. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pfizer Inc CDR Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pfizer Inc CDR. The current macd is -0.09496871.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pfizer price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Pfizer. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Pfizer price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Pfizer Inc CDR Daily Moving Average Convergence/Divergence (MACD) ChartPfizer Inc CDR Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pfizer Inc CDR. The current adx is 13.36.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Pfizer shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Pfizer Inc CDR Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pfizer Inc CDR. The current sar is 13.84.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Pfizer Inc CDR Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pfizer Inc CDR. The current rsi is 37.69. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Pfizer Inc CDR Daily Relative Strength Index (RSI) ChartPfizer Inc CDR Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pfizer Inc CDR. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pfizer price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Pfizer Inc CDR Daily Stochastic Oscillator ChartPfizer Inc CDR Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pfizer Inc CDR. The current cci is -127.31522057.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Pfizer Inc CDR Daily Commodity Channel Index (CCI) ChartPfizer Inc CDR Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pfizer Inc CDR. The current cmo is -35.01439978.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Pfizer Inc CDR Daily Chande Momentum Oscillator (CMO) ChartPfizer Inc CDR Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pfizer Inc CDR. The current willr is -94.11764706.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Pfizer Inc CDR Daily Williams %R ChartPfizer Inc CDR Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pfizer Inc CDR.

Pfizer Inc CDR Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pfizer Inc CDR. The current atr is 0.2387016.

Pfizer Inc CDR Daily Average True Range (ATR) ChartPfizer Inc CDR Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pfizer Inc CDR. The current obv is -1,747,077.

Pfizer Inc CDR Daily On-Balance Volume (OBV) ChartPfizer Inc CDR Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pfizer Inc CDR. The current mfi is 19.75.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Pfizer Inc CDR Daily Money Flow Index (MFI) ChartPfizer Inc CDR Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pfizer Inc CDR.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-06-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-17STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-07-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-26MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-31RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-08-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Pfizer Inc CDR Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pfizer Inc CDR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.692
Ma 20Greater thanMa 5013.500
Ma 50Greater thanMa 10013.537
Ma 100Greater thanMa 20013.431
OpenGreater thanClose13.270
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Pfizer with someone you think should read this too:
  • Are you bullish or bearish on Pfizer? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pfizer? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pfizer Inc CDR

I send you an email if I find something interesting about Pfizer Inc CDR.


Comments

How you think about this?

Leave a comment

Stay informed about Pfizer Inc CDR.

Receive notifications about Pfizer Inc CDR in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.